Rani Therapeutics Holdings, Inc. (RANI)
|Net Income (ttm)||-16.95M|
|Day's Range||18.63 - 19.70|
|52-Week Range||9.24 - 29.40|
|Price Target||24.60 (+27.5%)|
|Est. Earnings Date||Nov 15, 2021|
Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise ther... [Read more...]
In 2020, RANI's revenue was $462,000, a decrease of -52.81% compared to the previous year's $979,000. Losses were -$16.70 million, -37.18% less than in 2019.Financial Statements
- IPO in July 2021 raised $84.3 million in gross proceeds - - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership team with key management and board of directors' appointments -
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ:RXST), an ophthalmology-focused MedTech ...
Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purch...
SAN JOSE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technolo...
Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday. According to S-1 filings, shares were estimated to price between $14 and $16 last week.
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), a San Jose, California-based early stage biopharma, debuted Friday on the Nasdaq in its initial public offering. Rani Shares Trade Around IPO Price: Rani...
SAN JOSE, Calif., July 30, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to enable...
One company was launched by the venture capital firm led by Genentech's first scientist; the other by an inventor of an early defibrillator.
Rani Therapeutics Holdings, Inc. has filed to go public with an IPO on the NASDAQ.